Clinical Study

n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes

Table 2

Kinetic parameters of apoB-48 in TRL and apoB-100 in VLDL following supplementation with n-3 PUFA in patients with type 2 diabetes.

Placebo ()n-3 PUFA ()%

TRL apoB-48
 Pool size, mg99 ± 6296 ± 62−2.60.9
 Fractional catabolic rate, pools/day6.9 ± 3.87.6 ± 2.8+10.00.3
 Production rate, mg/kg/day5.4 ± 3.26.0 ± 3.8+11.10.7
VLDL apoB-100
 Pool size, mg600 ± 258594 ± 321−0.90.9
 Fractional catabolic rate, pools/day6.9 ± 2.36.9 ± 2.40.9
 Production rate, mg/kg/day35.6 ± 12.633.9 ± 12.4−5.60.6

PUFA: polyunsaturated fatty acid.
TRL: triglyceride-rich lipoproteins.
Mean ± SD; % represents the percentage of difference between the two intervention phases.